Biocon Biologics completes integration of Viatris' biosimilar business in 120 countries

In the final phase of integration, over 10 Emerging Markets, including Japan, Australia, and New Zealand, have transitioned as part of the biosimilars business acquisition from Viatris.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Biocon Biologics Ltd, a subsidiary of Biocon Ltd, has successfully completed the transition of the acquired biosimilars business in approximately 120 countries across Advanced and Emerging Markets, achieving this milestone a year ahead of schedule.

In the final phase of integration, over 10 Emerging Markets, including Japan, Australia, and New Zealand, have transitioned as part of the biosimilars business acquisition from Viatris, the company said in a press release. With the completion of this transition, Biocon Biologics has transformed into a fully integrated 'lab to market' biosimilars company, dedicated to serving millions of patients globally.

Earlier in 2023, the integration process included over 70 Emerging Markets in July, the North America business in September, and the European business in November.

Biocon Biologics now has commercial footprint across approximately 120 countries, directly present in the United States, Canada, Europe, and nine key Emerging Market countries, namely India, UAE, Saudi Arabia, Morocco, South Africa, Brazil, Malaysia, Thailand, and the Philippines.

All biosimilar brands acquired from Viatris, such as Ogivri & Hertraz (bTrastuzumab), Abevmy (bBevacizumab), Fulphila (bPegfilgrastim), Hulio (bAdalimumab), Nepexto (bEtanercept), Semglee (bGlargine), and Kirsty (bAspart), will now be marketed by Biocon Biologics teams. These products, developed by Biocon Biologics, are manufactured at the company's world-class facilities in India and Malaysia, covering key therapeutic areas of diabetology, oncology, and immunology. Pegfilgrastim is among the leading biosimilars in its segment with a double-digit market share in the United States. Trastuzumab is among the leading biosimilars in its category in several APAC, AFMET and LATAM countries.

Susheel Umesh, Chief Commercial Officer - Emerging Markets, Biocon Biologics, commented on the achievement, stating, “This presents a unique opportunity for our teams to take Brand Biocon Biologics directly to many markets. This self-led business model in key Emerging Markets will take us closer to patients, MoHs, prescribers, and payers. It will allow us to expand affordable access to larger patient pools in these Emerging Markets, thus enabling equitable access to high-quality biosimilars.”

The company is addressing the challenge of insulin inequity in many Emerging Markets through its affordable and high-quality biosimilar insulins, where recombinant human insulin and insulin glargine hold a dominant market share in countries like Mexico, Malaysia, Dominican Republic, Malawi, Tanzania, Mozambique etc., the press release added.